UK-India Collaboration to Develop Laser Technologies Announced
Laser scientists and engineers from the United Kingdom and India will collaborate under a new innovation programme to develop fresh laser technologies that will have the potential to boost the economies of both countries.
Funded by UK Research and Innovation (UKRI), with the UK lead being the Science and Technology Facilities Council’s (STFC) Central Laser Facility (CLF), the £4 million Extreme Photonics Innovation Centre (EPIC) will be housed in laboratories set up at TIFR Hyderabad. The project will focus on developing and exploiting laser techniques for economic and societal impact. The joint UK and India scheme will use particle and x-ray beams with the aim of revolutionising a range of areas of healthcare, such as high-resolution imaging, therapeutic and biomedical applications to tackle health problems.
Speaking about EPIC the Central Laser Facility Director Professor John Collier said: “These new accelerators can deliver very bright particle and x-ray beams that could be used for high-resolution industrial and biomedical imaging, and for therapeutic applications.”
“CLF is a world-leader in exploiting these novel accelerators and we’ll build on our long-standing collaboration with the Tata Institute of Fundamental Research
Inovus Medical Expands its Sales Team and Operations in South East Asia
Inovus Medical is pushing ahead with plans to grow its sales team and operations in South East Asia, a key target market for which Inovus products are ideally suited. Entry into the Philippines market was announced with attendance at the MIGS: East Meets West - PSGE 15th Annual Convention and 1st Regional Meeting of ESGE & APAGE in East Asia held on the 14th - 17th August at the EDSA Shangri-La Hotel Mandaluyong City.
The meeting is a fi rst in collaboration of the European Society for Gynaecological Endoscopy and the Asia-Pacifi c Association for Gynaecologic Endoscopy and an ideal platform for Inovus to showcase some of its latest bozziniTM Hysteroscopy Basic and bozziniTM
Hysteroscopy simulators
The move into South East Asia demonstrates Inovus’ commitment to becoming the leading surgical simulation provider in one of the worlds high-growth markets. Southeast Asia’s growing technology market holds
enormous promise due to the region’s massive young, tech-savvy population and is fast establishing credentials as a base for high-tech industries and value-added manufacturing making the region a perfect fi t for Inovus and the innovative surgical simulation products the company designs and manufactures.
Dr Elliot Street, CEO Inovus Medical, said: “We are excited to be able to offer our full suite of surgical simulators in SEA, a key target market for us and one we feel will offer great potential for growth of our export activity. Our newly appointed Asia representative will be offering full support to our distributors on the ground and making sure our affordable and functional simulators make their way into the hands of surgeons across the region.”
50266pr@reply-direct.com
Shionogi Partners with The AMR Centre for New Superbug Therapy
The AMR Centre Ltd has announced a landmark agreement with the Japanese pharma company Shionogi to take forward its anti-virulence program, COT-143. The therapy is designed to help the body tackle Pseudomonas aeruginosa infections, a hard to treat drug-resistant pathogen recognised by the WHO as a critical threat to human health.
COT-143 is a novel humanised monoclonal antibody. It does not kill bacteria directly but targets an element that prevents the immune system from acting against the infection. COT-143 has already produced encouraging results in pre-clinical studies and regulatory toxicology tests in preparation for fi rst- in-human clinical trials. The AMR Centre will further develop the program,
taking it through a Good Manufacturing Practice clinical manufacturing campaign. It is in discussions about conducting phase one and phase two clinical trials at The Royal Liverpool University Hospital in 2020.
With the completion of this agreement, The AMR Centre, which is based at Alderley Park, Cheshire, will hold the exclusive worldwide right of research, development and manufacturing of COT-143. Shionogi, a global business with headquarters in Osaka, will share in revenues if the project progresses to market.
50275pr@reply-direct.com (TIFR) whose expertise in this area will help us develop this work further.”
Professor V. Chandrasekhar, Centre Director, TIFR Hyderabad said of the new collaboration: “TIFR has a long tradition of research on lasers and plans to initiate new activities based on intense petawatt lasers at its Hyderabad campus. With this background TIFR is collaborating with the CLF team to develop state of the art technologies that will be of great benefi t to both India and UK.”
EPIC’s UK Lead, Dr Rajeev Pattathil, said experiments using CLF’s existing high power laser systems had already demonstrated the potential application of the new accelerators in industry, engineering, science, medicine, and advanced materials.
“Working with India on developing further the technologies that transform novel accelerators to real world applications will be mutually benefi cial as India aspires to have a strong research programme in this area through the recently announced expansion of the TIFR centre in Hyderabad that will house EPIC.”
50246pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124
